There are roughly 2 cents per share of expenses associated with the acquisition. That makes for roughly .11 before non recurring expenses. In line with last quarter if I remember correctly.
From the press release... “We strengthened further our financial position as the clinical development of SGI-110 proceeds and as we prepare our most advanced clinical-stage drug, amuvatinib, to enter a Phase II clinical trial by midyear.”
Well geez... they have been "preparing" Amuvatinib for phase 2 trials for the last 12 months. Get it into the clinics already!!!!!
This is why the stock doesn't respond to these positive earnings reports. They just keep sitting on their hands.
By the way, if Astex cash equals the 25 million they are paying up front, they can pay the additional 30 million in cash and still have roughlt 100 million in the bank after the transaction closes.